Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
29.8M
-
Shares change
-
-1.23M
-
Total reported value, excl. options
-
$121M
-
Value change
-
-$7.13M
-
Number of buys
-
14
-
Number of sells
-
-21
-
Price
-
$4.05
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q4 2016
48 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q4 2016.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.8M shares
of 1.57B outstanding shares and own 1.9% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (9.88M shares), FMR LLC (7.07M shares), Capital World Investors (4.48M shares), BAILLIE GIFFORD & CO (921K shares), FIL Ltd (754K shares), ORBIMED ADVISORS LLC (724K shares), Rock Springs Capital Management LP (675K shares), MILLENNIUM MANAGEMENT LLC (672K shares), QVT Financial LP (657K shares), and Tekla Capital Management LLC (566K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.